University of Minnesota
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT05227404
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Minneapolis, Minnesota, 55455, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Point-of-care test for SARS-CoV-2
Point-of-care test for SARS-CoV-2
Genscript assay performed on the plasma sample
Time frame: an average of 1 day
LumiraDx test and GenScript assay are two ways to determine the presence of antibodies to SARS-CoV-2. This measure is a comparison to check agreement between the two tests' results. This is a comparison of the proportion of the positive tests. The comparison is made by looking at the difference of the two proportions obtained by the two tests, so the measure is unitless.
Time frame: an average of 1 day
RightSign test and GenScript assay are two ways to determine the presence of antibodies to SARS-CoV-2. This measure is a comparison to check agreement between the two tests' results. This is a comparison of the proportion of the positive tests. The comparison is made by looking at the difference of the two proportions obtained by the two tests, so the measure is unitless.
Time frame: an average of 1 day
The frequency with which the LumiraDx test fails to give an unambiguous result
Time frame: an average of 1 day
The frequency with wich the RightSign test fails to give an unambiguous result
University of Minnesota
Other
Evaluation of the Feasibility and Reproducibility of 2 Point-of-Care Tests for SARS-Co-V-2 Antibodies (INSIGHT 017)
Acronym: (EPOC)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06633835
COVID-19, Coronaviridae Infections
Salt Lake City, Utah, United States
View Trial DetailsNCT06065176
COVID-19, Coronaviridae Infections
Salt Lake City, Utah, United States
View Trial DetailsNCT05178173
COVID-19, Coronaviridae Infections
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05372588
COVID-19, Coronaviridae Infections
Bruce, Australian Capital Territory, Australia
View Trial Details